Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD

Bone Marrow Transplantation

Volumn 46, Issue 3, 2011, Pages 430-435

  Rager, A ^a   Frey, N ^a   Goldstein, S C ^a   Reshef, R ^a   Hexner, E O ^a   Loren, A ^a   Luger, S M ^a   Perl, A ^a   Tsai, D ^a   Davis, J ^a   Vozniak, M ^a   Smith, J ^a   Stadtmauer, E A ^a   Porter, D L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cytokines; daclizumab; GVHD; infliximab; steroid refractory

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; DACLIZUMAB; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RITUXIMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STEROIDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79952533271     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.117     Document Type: Article

References (31)

1. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472. (Pubitemid 20364008)
2. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplant-ation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030. (Pubitemid 20067206)
3. Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR, Ramsay NK et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conven-tional therapy. Bone Marrow Transplant 1992; 10: 77-82.
4. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: compar-ison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-394.
5. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-160. (Pubitemid 34285074)
6. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059-1064. (Pubitemid 32591189)
7. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821-1828.
8. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119-4126. (Pubitemid 46743372)
9. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181-187. (Pubitemid 37288503)
10. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654. (Pubitemid 38970556)
11. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89. (Pubitemid 30017229)
12. Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J et al. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 1116-1121.
13. Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007; 40: 481-486. (Pubitemid 47288229)
14. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124: 777-786. (Pubitemid 38365783)
15. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer 2007; 49: 212-215. (Pubitemid 47041116)
16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
17. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-864. (Pubitemid 27321388)
18. Kaplan EL MP. Non parametric estimation from incomplete observations. JAm Stat Assoc 1958; 53: 457-481.
19. Cornfield J GT, Smith WW. Quantal response curves for experimentally uncontrolled variables. Bull Int Stat Inst 1961; 38: 97-115.
20. Antin JH, Chen A, Couriel D, Ho V, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplantation 2004; 10: 655-668. (Pubitemid 39272870)
21. Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006; 135: 382-385. (Pubitemid 44484847)
22. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47-49. (Pubitemid 32707616)
23. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004; 89: 1352-1359. (Pubitemid 39540573)
24. Schmidt-Hieber M, Fietz T, Knauf W, Uharek L, Hopfen-muller W, Thiel E et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005; 130: 568-574. (Pubitemid 43899761)
25. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820-823. (Pubitemid 32222858)
26. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35: 1003-1010. (Pubitemid 40711838)
27. Srinivasan R, Geller N, Dorrance C, Espinoza-Delgado I, Barrett AJ, Takahashi Y et al. High response rates and acute steroid refractory graft-versus-host disease (GVHD) following combined tumor necrosis factor alpha (TNF-a) and inter-leukin-2 (IL-2) blockade. Blood 2005; 106: 1801a.
28. Rao K, Rao A, Karlsson H, Jagani M, Veys P, Amrolia PJ. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol 2009; 31: 456-461.
29. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-2776. (Pubitemid 37258330)
30. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy Jr PL et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559-1564. (Pubitemid 39166538)
31. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the blood and marrow transplant clinical trials network. Blood 2009; 114: 511-517.